WHO Expert Committee on Drug Dependence (PDF)
Thirty-fifth Report
Technical Report Series, No 973
ISBN-13    9789240689688 ISBN-10    9240689680
Order Number    18000121 Format    PDF
Price    CHF    14.00 / US$    16.80 Developing countries:    CHF    9.80
English     2012        30   pages
Summary
Table of contents
Related Publications
Translation(s) available
 
   Add to your order
 
 
Summary
This report presents the recommendations of a WHO Expert Committee responsible for reviewing information on psychoactive substances to assess the need for their international control.

The report contains a summary of the Committee s evaluations of y-hydroxybutyric acid (GHB) and ketamine. GHB was recommended to be rescheduled from Scheduleá IV to Schedule II of the Convention on Psychotropic Substances.

The report also discusses the nine substances that were prereviewed: dextromethorphan, tapentadol, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), 1-(3-chlorophenyl)piperazine (mCPP), 1-(4-methoxyphenyl) piperazine (MeOPP), 1-(3,4-methylenedioxybenzyl)piperazine (MDBP), y-butyrolactone (GBL), and 1,4-butanediol (1,4-BD). Of these, tapentadol, BZP, GBL and 1,4-BD were recommended for critical review. Issues identified for consideration at future Expert Committee meetings are also listed.

Furthermore, the report discusses the use of terms, the use of pharmacovigilance data for the assessment of abuse and dependence potential, balancing medical availability and prevention of abuse of medicines manufactured from controlled substances, and improving the process for substance evaluation.